(icTV) CLINICAL TRIALS RESULTS ~ Plasma angiopoietin-2 & ARDS risk in sepsis

(icTV) CLINICAL TRIALS RESULTS Plasma angiopoietin-2 & ARDS risk in sepsis In this icTV interview, presenter John Reilly discusses his clinical trial “Plasma angiopoietin-2 as a potential causal marker in sepsis-associated ARDS development: Evidence from mendelian randomisation and mediation analysis”. Full results from this trial were presented at the clinical trials session at LIVES 2018 […]

Read More…

Post-EOLIA trial: What’s the role of ECMO?

CLINICAL TRIAL RESULTS ECMO Bayesian analysis Following publication of the EOLIA trial, many questions remain as to the role of early venovenous extracorporeal membrane oxygenation (ECMO) in very severe ARDS.  In this icTV interview, Ewan Goligher (Toronto, Canada) describes the results of a post hoc Bayesian analysis of the EOLIA trial conducted to determine the […]

Read More…